SPHS Sophiris Bio Inc.

2.07
-0.08  -4%
Previous Close 2.15
Open 2.12
Price To Book -15.92
Market Cap 62330087
Shares 30,111,153
Volume 160,486
Short Ratio
Av. Daily Volume 226,127

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 181224325
  2. 8-K - Current report 181224310
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181178232
  4. 8-K - Current report 181177946
  5. 8-K - Current report 181047142

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b complete data due by end of 2018.
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 3 primary endpoints met - November 2015. Second Phase 3 trial dependent on funding.
Topsalysin (PRX302)
Benign prostatic hyperplasia

Latest News

  1. Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price?
  2. SPHS: Data from Second Administration of Topsalysin in Phase 2b Trial Anticipated Before End of 2018…
  3. Report: Exploring Fundamental Drivers Behind HC2, Pangaea Logistics Solutions, Sophiris Bio, Acacia Research, JAKKS Pacific, and LeMaitre Vascular — New Horizons, Emerging Trends, and Upcoming Developments
  4. Sophiris Bio to Present at the Piper Jaffray Healthcare Conference
  5. Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
  6. Sophiris Bio to Present at the Cantor Global Healthcare Conference
  7. Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement
  8. SPHS: Patient Death in Phase 2b Trial Unlikely Related to Topsalysin Treatment…
  9. Today’s Research Reports on Stocks to Watch: Opiant Pharmaceuticals and Sophiris Bio
  10. Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference
  11. Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial
  12. SPHS: Ready to Advance Topsalysin into Registration Studies…
  13. Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
  14. SPHS: Interim Data Reported for P2b Study of Topsalysin in Localized Prostate Cancer
  15. Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Sophiris
  16. Today's Research Reports on Trending Tickers: Sophiris Bio and Achaogen
  17. Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer
  18. Want To Invest In Sophiris Bio Inc (NASDAQ:SPHS)? Here’s How It Performed Lately
  19. SPHS: Countdown to Release of Topline Data for Phase 2b Study of Topsalysin in Prostate Cancer at end of 2Q18

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 181224325
  2. 8-K - Current report 181224310
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181178232
  4. 8-K - Current report 181177946
  5. 8-K - Current report 181047142
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181017582
  7. 8-K - Current report 181017450
  8. CT ORDER - Confidential treatment order 18990814
  9. 8-K - Current report 18925746
  10. 8-K - Current report 18916094